Type 2 diabetes treatment has changed a lot in just a few years. New medicines can lower blood sugar in ways that once seemed out of reach. That is good news, and it can also feel like a lot.
The hard part is no longer finding options. It is knowing which one fits you, what the evidence shows, and what to ask before you start.
This guide walks through every main option in plain terms. You will see how each one works, what the trials found, and the questions worth asking your doctor.
KEY TAKEAWAYS
- Type 2 diabetes can be managed well, though no medicine can cure it.
- Lifestyle habits are the foundation, and most people add medicine over time.
- Metformin is the long-standing first medicine for many adults with type 2 diabetes.
- GLP-1 brands like Ozempic®, Rybelsus®, and Victoza® were tested in large trials.
- Ozempic®, Rybelsus®, Victoza®, and Mounjaro® carry an FDA boxed warning for thyroid C-cell tumors.
What readers want to figure out
- You want a plain explanation of what type 2 diabetes treatment involves today.
- You want to know where metformin fits and why it is still first for many.
- You want the real story on GLP-1 brands like Ozempic® and Mounjaro®.
- You want to understand the boxed warning and other safety cautions.
- You want smart questions to bring to your doctor before you choose.
What type 2 diabetes actually is
Type 2 diabetes means your blood sugar runs too high over time. Your body still makes insulin, the hormone that moves sugar into cells. The problem is that your cells stop responding to it well.
Doctors call that insulin resistance. Sugar then builds up in your blood instead of fueling your body. Early signs can include thirst, tiredness, and frequent trips to the bathroom.
Type 2 diabetes usually builds slowly over years. Family history, weight, age, and activity level all play a role. It is very common, and you are far from alone.
Your care team tracks control with an A1c test. A1c shows your average blood sugar over about three months. An A1c of 6.5 percent or higher points to diabetes.
Here is what the common numbers mean.
| A1c level | What it usually means |
|---|---|
| Below 5.7% | Normal range |
| 5.7% to 6.4% | Prediabetes |
| 6.5% or higher | Type 2 diabetes, confirmed on two tests |
| Below 7% | A common goal for many adults with diabetes |
Type 2 diabetes is a long-term condition you manage, not a problem you cure. The goal is steady blood sugar and lower risk to your heart and kidneys. Many people reach that goal and feel much better.
Type 2 diabetes is a condition you manage day by day, not a moral failing you fix overnight.
Why blood sugar control matters
Steady blood sugar protects the rest of your body. Over years, high blood sugar can harm your heart, kidneys, eyes, and nerves. Good control lowers those risks.
That is the real reason treatment matters. It is not only about a number on a lab report. It is about protecting how you feel and function for decades.
The good news is that small improvements add up. Even a modest drop in your A1c can lower your risk. You do not need to be perfect to benefit.
Lifestyle: the foundation under every plan
Every good plan starts with daily habits. These habits work on their own, and they make medicines work better too.
The main areas are simple to name and harder to live. Small, steady changes tend to last longer than big crash efforts.
- Nutrition: fill half your plate with vegetables, and cut back on sugary drinks and refined carbs.
- Activity: aim for about 150 minutes of moderate movement each week, like brisk walking.
- Sleep: poor sleep can raise blood sugar, so a steady sleep routine helps.
- Weight: losing even 5 to 10 percent of your body weight can lower your A1c.
Lifestyle alone is often not enough once diabetes sets in. That is not a personal failure. Most people pair healthy habits with one or more medicines.
A diabetes educator or dietitian can make this easier. Many clinics offer classes that insurance may cover. Ask for a referral if these habits feel hard to change alone.
Metformin: the long-standing first-line medicine
Metformin is a pill that has helped people with type 2 diabetes for decades. It belongs to a class called biguanides. It is FDA approved and widely used.
Metformin works mainly by lowering the sugar your liver makes. It also helps your body respond to insulin again. On its own, it rarely causes low blood sugar.
Common side effects are stomach related, like nausea or loose stools. These often ease over a few weeks. Over the long term, metformin can lower vitamin B12, so your doctor may check it.
A very rare risk is a buildup of acid in the blood, called lactic acidosis. It is uncommon in people with healthy kidneys. Your doctor screens for it before you start.
Metformin also pairs well with newer medicines. Many people take it alongside a GLP-1 or SGLT2 inhibitor. The combination can lower blood sugar more than either one alone.
Metformin is still a first choice for many adults. In 2026, though, the choice depends on your whole health picture. If you have heart or kidney disease, your doctor may start a different medicine early.
GLP-1 receptor agonists
GLP-1 medicines copy a gut hormone your body makes after meals. That hormone lowers blood sugar and helps you feel full. These medicines are a major reason treatment has improved.
The brands below are FDA approved, and each was tested in its own large trial. The results belong to those branded products.
These medicines share some common side effects. Nausea, and sometimes vomiting or loose stools, show up most often. They usually fade as your body adjusts, and a slow dose increase helps.
How you take them varies by brand. Some are weekly shots, one is a daily shot, and one is a daily pill. Your preference is part of the choice.
Ozempic® (semaglutide)
Ozempic® (the brand of semaglutide) is a once weekly shot. The FDA approved it for type 2 diabetes in 2017. It lowers blood sugar and can also lower heart risk.
In the SUSTAIN-6 trial, 3,297 adults with heart risk took Ozempic® or a placebo. Major heart events happened in 6.6 percent on Ozempic®, versus 8.9 percent on placebo.
Rybelsus® (oral semaglutide)
Rybelsus® (the brand of oral semaglutide) is a daily pill. It is the same medicine as Ozempic®, made to survive the stomach. The FDA approved it for type 2 diabetes in 2019.
In the PIONEER 1 trial, 703 adults took Rybelsus® or a placebo for 26 weeks. The top dose lowered A1c by about 1.4 percent from a starting point near 8 percent.
Victoza® (liraglutide)
Victoza® (the brand of liraglutide) is a daily shot. The FDA approved it for type 2 diabetes in 2010. It was one of the first in this class to show heart benefits.
In the LEADER trial, 9,340 adults took Victoza® or a placebo. Major heart events happened in 13.0 percent on Victoza®, versus 14.9 percent on placebo.
Each brand earns its claims from its own named trial, not from the class as a whole.
GIP and GLP-1: Mounjaro® (tirzepatide)
Mounjaro® (the brand of tirzepatide) works on two gut hormone signals at once, GIP and GLP-1. That dual action is what sets it apart. It is a once weekly shot.
The FDA approved Mounjaro® for type 2 diabetes in May 2022. In the SURPASS-1 trial, 478 adults took Mounjaro® as their only diabetes medicine. A1c fell by up to about 2 percent, and up to 92 percent reached an A1c below 7 percent.
In the SURPASS-2 trial, 1,879 adults took Mounjaro® or Ozempic® (semaglutide) 1 mg, each added to metformin. Mounjaro® lowered A1c and body weight more than Ozempic® in that study.
Mounjaro® shares the same stomach side effects as the GLP-1 group. It can also lead to notable weight loss, which many people welcome. Your doctor raises the dose slowly to limit nausea.
The boxed warning you should know about
The GLP-1 and GIP medicines carry the strongest safety alert the FDA uses. It is called a boxed warning. It applies to Ozempic®, Rybelsus®, Victoza®, and Mounjaro®.
In animal studies, these medicines caused thyroid C-cell tumors in rodents. Scientists do not yet know if the same risk applies to people. The label states this plainly.
Because of this, these medicines are not for everyone. You should not take them if you or a close family member had medullary thyroid carcinoma. The same goes for a rare inherited condition called multiple endocrine neoplasia type 2, or MEN 2.
Tell your doctor about your family history before you start. This one question can rule a whole class in or out.
For most people without that history, doctors still prescribe these medicines widely. The warning is about a specific risk in specific people. It is a reason to share your history, not a reason to fear the whole class.
Before any GLP-1 or GIP medicine, your family thyroid history is the first thing to share.
SGLT2 inhibitors and insulin: other standard options
Two more standard options round out most plans. Your doctor may reach for them based on your other health needs.
SGLT2 inhibitors
SGLT2 inhibitors help your kidneys pass extra sugar out in your urine. Brands include Jardiance® (empagliflozin) and Farxiga® (dapagliflozin). They also help protect the heart and kidneys.
In the EMPA-REG OUTCOME trial, 7,020 adults took Jardiance® (empagliflozin) or a placebo. It lowered the risk of hospital stays for heart failure.
Doctors often choose an SGLT2 inhibitor when heart failure or kidney disease is part of your picture. The heart and kidney benefits are a big reason why.
A rare but serious risk is diabetic ketoacidosis, a dangerous buildup of acid. It can happen even when blood sugar looks near normal. Learn the warning signs with your doctor.
Insulin
Insulin is the hormone your body cannot use well in diabetes. As a medicine, it adds back what your body needs. Doctors often use it when blood sugar is very high.
Insulin is not a last resort or a punishment. Sometimes it is simply the safest, fastest way to steady your levels. Its main cautions are low blood sugar and some weight gain.
Long acting insulin gives a steady background level. Rapid acting insulin covers your meals. Your plan may use one type or both.
Older pills like sulfonylureas
Sulfonylureas are older, low cost pills, such as glipizide and glimepiride. They push your pancreas to release more insulin. Their main cautions are low blood sugar and weight gain.
Your type 2 diabetes treatment options at a glance
Here is a side by side view of the main options. No prices appear here, since cost depends on your plan and pharmacy.
| Drug class | Example brand | How it helps | Key caution |
|---|---|---|---|
| Lifestyle habits | Not a drug | Lowers A1c and boosts every medicine | Hard to sustain without support |
| Metformin (biguanide) | Standard generic | Lowers sugar the liver makes | Stomach upset, rare lactic acidosis |
| GLP-1 receptor agonist | Ozempic®, Rybelsus®, Victoza® | Lowers blood sugar and appetite | Boxed warning: thyroid C-cell tumors |
| GIP and GLP-1 agonist | Mounjaro® | Lowers blood sugar and weight strongly | Boxed warning: thyroid C-cell tumors |
| SGLT2 inhibitor | Jardiance®, Farxiga® | Protects the heart and kidneys | Rare diabetic ketoacidosis |
| Insulin | Many brands | Adds the hormone your body lacks | Low blood sugar, weight gain |
| Sulfonylurea | Standard generic | Prompts more insulin release | Low blood sugar, weight gain |
How the choice gets personalized
There is no single best medicine for everyone. The 2026 ADA Standards of Care match the medicine to your health picture. Your heart, kidneys, weight, and low sugar risk all matter.
A big shift is that A1c is no longer the only goal. Protecting your heart and kidneys now sits right beside blood sugar control.
You are part of this choice too. Your goals, your comfort with shots or pills, and your daily life all count. The best plan is one you understand and agree with.
- Heart disease: a GLP-1 medicine or SGLT2 inhibitor with proven heart benefit often comes first.
- Heart failure: an SGLT2 inhibitor is preferred, whatever your A1c.
- Kidney disease: an SGLT2 inhibitor helps protect the kidneys, with GLP-1 options too.
- Weight a priority: a GLP-1 or the GIP and GLP-1 medicine tends to help most.
- Low blood sugar worry: your doctor may avoid sulfonylureas and use insulin with care.
Your daily routine matters too. A weekly shot suits some people, while others prefer a daily pill. An open talk about your routine leads to a plan you can keep.
This is why two people with the same A1c can leave with different plans. Your plan should reflect you.
What to expect when starting a new medicine
Starting a new diabetes medicine is a process, not a switch you flip. Most plans begin at a low dose. Your doctor raises it slowly to limit side effects.
You will likely check in within a few weeks or months. Together you will look at your blood sugar, your side effects, and how you feel. Small changes early on are normal.
Questions to ask your doctor
Bring this list to your visit. A focused talk is the best way to land on a plan that fits.
- Given my A1c, weight, and heart and kidney health, which options fit me best?
- Should I start with metformin, or does my health point to another medicine first?
- If a GLP-1 or GIP medicine is an option, does my family history rule it out?
- What are the most common side effects, and which warning signs are serious?
- How long will I stay on this medicine, and what happens if I stop?
- How often will we check my A1c and adjust the plan?
- Besides blood sugar, how will we protect my heart and kidneys?
- What lifestyle changes will help most for someone like me?
- Will my insurance cover this, and what are my options if it does not?
- If this plan is not working in three months, what is our next step?
Write down the answers, and ask for anything you want in writing. A good clinician welcomes these questions.
How to prepare for your appointment
A little prep makes the whole visit better. Walk in knowing your numbers, your history, and your goals.
- Bring recent labs if you have them, especially your latest A1c.
- List every medicine and supplement you take, since some can interact.
- Note your family history, especially thyroid cancer or MEN 2.
- Track a few days of meals and activity to spot patterns.
- Write down your top goal in plain words, like more energy each day.
Bring a partner or friend if the visit feels like a lot. A second set of ears helps you remember the plan.
The Bottom line
Type 2 diabetes treatment in 2026 is more flexible and more hopeful than before. It starts with daily habits and often adds metformin. From there, your heart, kidneys, and weight guide the next step.
GLP-1 brands like Ozempic®, Rybelsus®, and Victoza®, plus the GIP and GLP-1 brand Mounjaro®, gave strong trial results. They also carry a boxed warning worth a careful talk. The best plan is the one you and your doctor build together.
FREQUENTLY ASKED QUESTIONS
Lifestyle habits come first for everyone, and metformin is still the most common first medicine. The 2026 ADA Standards of Care changed the next step. If you have heart disease, heart failure, or kidney disease, the plan may shift. Your doctor may add a GLP-1 medicine or an SGLT2 inhibitor early, based on your needs, not your A1c alone.
No medicine cures type 2 diabetes, and it is best seen as a long-term condition you manage. The encouraging part is that management works well. With steady habits, the right medicine, and regular checkups, many people keep their blood sugar in a healthy range. That also lowers the risk of other problems over time.
An A1c of 6.5 percent or higher, confirmed on two tests, points to diabetes. An A1c between 5.7 and 6.4 percent is prediabetes, and below 5.7 percent is normal. Many adults with diabetes aim for an A1c below 7 percent, though your doctor may set a goal that fits you.
There is no single best option for everyone. Ozempic®, Rybelsus®, and Victoza® each lowered blood sugar in their own large trials. The right choice depends on your health, your preferences, and how you like to take it. A daily pill, a daily shot, and a weekly shot are all possible.
Ozempic®, Rybelsus®, Victoza®, and Mounjaro® carry an FDA boxed warning because they caused thyroid C-cell tumors in rodents. Scientists do not know if the same risk applies to people. As a precaution, these medicines are not for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.
Ozempic® (semaglutide) acts on one gut hormone signal, GLP-1. Mounjaro® (tirzepatide) acts on two signals, GIP and GLP-1. In the SURPASS-2 trial of 1,879 adults, Mounjaro® lowered A1c and body weight more than Ozempic®. Both are weekly shots, and both carry the same thyroid boxed warning.
Not always. Doctors sometimes use insulin early when blood sugar is very high, then step back later. Other times it is added when other medicines are not enough. Insulin is a safe, well understood tool. Its main cautions are low blood sugar and some weight gain, which your care team helps you manage.
Three habits do the heavy lifting. Eating more vegetables and fewer sugary drinks steadies blood sugar. Moving about 150 minutes a week helps your body use insulin. Losing 5 to 10 percent of your body weight can lower your A1c. Better sleep supports all three, so a steady bedtime helps too.
KEEP READING
Comparing GLP-1 providers
If you and your doctor land on a GLP-1 medicine, the next question is where to get care. See how the main GLP-1 providers compare on how they operate.
→ Read next: /compare/best-glp1-programs/
SOURCES
1. American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes 2026. Diabetes Care. 2026;49(Suppl 1):S183. https://diabetesjournals.org/care/article/49/Supplement_1/S183/163934
2. Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844. https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
3. Aroda VR, et al. PIONEER 1: Efficacy and Safety of Oral Semaglutide Monotherapy in Type 2 Diabetes. Diabetes Care. 2019;42(9):1724-1732. https://diabetesjournals.org/care/article/42/9/1724/36289
4. Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. 2016;375:311-322. https://www.nejm.org/doi/full/10.1056/NEJMoa1603827
5. Rosenstock J, et al. Tirzepatide monotherapy in type 2 diabetes (SURPASS-1). Lancet. 2021;398:143-155. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01324-6/abstract
6. Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
7. Zinman B, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME). N Engl J Med. 2015;373:2117-2128. https://www.nejm.org/doi/full/10.1056/NEJMoa1504720
8. US Food and Drug Administration. OZEMPIC® (semaglutide) injection, Prescribing Information, Boxed Warning. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s009lbl.pdf
9. US Food and Drug Administration. MOUNJARO® (tirzepatide) injection, Prescribing Information, Boxed Warning. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
10. American Diabetes Association. Understanding A1C. https://diabetes.org/about-diabetes/a1c
Last updated: 2026-07-10 · Editorially reviewed by the Peptides.io team
Important notices & disclaimers
Editorial & medical: This guide is general education, not medical advice. Talk to a licensed clinician before starting, stopping, or changing any medication.
Affiliate disclosure: Peptides.io may earn a commission from links to providers — it never changes what you pay or how we rank them, and never influences our recommendations.
Compounded GLP-1 (FDA): Compounded semaglutide and tirzepatide are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality. They are not generic versions of, or equivalent to, branded medications such as Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. Clinical-trial results cited here apply only to those branded formulations — not to compounded preparations.
Comments